Related references
Note: Only part of the references are listed.Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in US Hospitals during 2016 to 2018
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and lsogenic β-Lactam-Resistant Mutants
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2020)
Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases
Laura Benchetrit et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
Renee Ackley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Epidemiology of beta-Lactamase-Producing Pathogens
Karen Bush et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia
David L. Paterson et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2020)
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units
Alyssa R. Golden et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2020)
Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam
Elske Sieswerda et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
David van Duin et al.
LANCET INFECTIOUS DISEASES (2020)
Multidrug-Resistant Bacterial Infections in US Hospitalized Patients, 2012-2017
John A. Jernigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study
Jeffrey R. Strich et al.
LANCET INFECTIOUS DISEASES (2020)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2019)
The Infectious Diseases Society of America's 10 x ′20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x ′20 a Possibility?
George H. Talbot et al.
CLINICAL INFECTIOUS DISEASES (2019)
International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia
Pranita D. Tamma et al.
JAMA INTERNAL MEDICINE (2019)
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia
Dee Shortridge et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae
Matthew C. Canver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates
Zachary S. Elliott et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2019)
Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae
M. Biagi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical
Luisa Sorli et al.
JOURNAL OF INFECTION (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations
Stephanie Ho et al.
CURRENT INFECTIOUS DISEASE REPORTS (2019)
Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States
Pranita D. Tamma et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs β-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
Chitra Punjabi et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data
Cornelius J. Clancy et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Charting the Path Forward: Development, Goals and Initiatives of the 2019 Infectious Diseases of America Strategic Plan
Cynthia L. Sears et al.
CLINICAL INFECTIOUS DISEASES (2019)
A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?
Kellie J. Goodlet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy
Claire Amaris Hobson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers
Cecilia G. Carvalhaes et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016
Fiona Senchyna et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center
Brandon Kulengowski et al.
PATHOGENS AND DISEASE (2019)
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
Evelyn Shaw et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from US Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women A Randomized Clinical Trial
Angela Huttner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
Pranita D. Tamma et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals
Menglan Zhou et al.
INFECTION AND DRUG RESISTANCE (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
Melissa D. Barnes et al.
MBIO (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
The global epidemiology of carbapenemase-producing Enterobacteriaceae
David van Duin et al.
VIRULENCE (2017)
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world
Yohei Doi et al.
JOURNAL OF TRAVEL MEDICINE (2017)
Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene
Ryota Ito et al.
MBIO (2017)
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial
Joseph Solomkin et al.
JAMA SURGERY (2017)
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature
Ryan K. Shields et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B
Maria Helena Rigatto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center
Samuel L. Aitken et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates
Christina A. Sutherland et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2016)
Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
Ruibin Wang et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013
Alice Y. Guh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period
Josef Yayan et al.
PLOS ONE (2015)
Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine US Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy
Kady Phe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram- Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium
Felipe F. Tuon et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters
Nan-Yao Lee et al.
CLINICAL INFECTIOUS DISEASES (2013)
Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
Ana M. Sandri et al.
CLINICAL INFECTIOUS DISEASES (2013)
Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center
Darowan S. Akajagbor et al.
CLINICAL INFECTIOUS DISEASES (2013)
Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms
Elizabeth A. Neuner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
Teena Chopra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Pranita D. Tamma et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
Kalpana Gupta et al.
CLINICAL INFECTIOUS DISEASES (2011)
Comparison of Nine Phenotypic Methods for Detection of Extended-Spectrum β-Lactamase Production by Enterobacteriaceae
Helene Garrec et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline
Matthew E. Falagas et al.
CURRENT DRUG METABOLISM (2009)
Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity
Maura S. Oliveira et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
Unreliable Extended-Spectrum β-Lactamase Detection in the Presence of Plasmid-Mediated AmpC in Escherichia coli Clinical Isolates
F. J. L. Robberts et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide
L. Drieux et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women
Kalpana Gupta et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Polymyxin B: similarities to and differences from colistin (polymyxin E)
Andrea Kwa et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Kenneth N. Agwuh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data
T Babinchak et al.
CLINICAL INFECTIOUS DISEASES (2005)
Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women - A randomized trial
TM Hooton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae
DS Burgess et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
